Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 397 entries
Sorted by: Best Match Show Resources per page
Prognostic value of k-ras 12 genotypes in patients with advanced nonsmall cell lung-cancer receiving Carboplatin with either intravenous or chronic oral dose Etoposide.

International journal of oncology

Rosell R, Li S, Anton A, Moreno I, Martinez E, Vadell C, Mate J, Ariza A, Monzo M, Font A, Molina F, Deanta J, Pifarre A.
PMID: 21559571
Int J Oncol. 1994 Aug;5(2):169-76. doi: 10.3892/ijo.5.2.169.

Despite the knowledge of strong prognostic factors such as stage and performance status, the outcome of individual patients with non-small cell lung cancer is not yet predictable, although it has been observed that patients whose tumors contain K-ras gene...

Cite
Rosell R, Li S, Anton A, et al. Prognostic value of k-ras 12 genotypes in patients with advanced nonsmall cell lung-cancer receiving Carboplatin with either intravenous or chronic oral dose Etoposide. Int J Oncol. 1994;5(2):169-76doi: 10.3892/ijo.5.2.169.
Rosell, R., Li, S., Anton, A., Moreno, I., Martinez, E., Vadell, C., Mate, J., Ariza, A., Monzo, M., Font, A., Molina, F., Deanta, J., & Pifarre, A. (1994). Prognostic value of k-ras 12 genotypes in patients with advanced nonsmall cell lung-cancer receiving Carboplatin with either intravenous or chronic oral dose Etoposide. International journal of oncology, 5(2), 169-76. https://doi.org/10.3892/ijo.5.2.169
Rosell, R, et al. "Prognostic value of k-ras 12 genotypes in patients with advanced nonsmall cell lung-cancer receiving Carboplatin with either intravenous or chronic oral dose Etoposide." International journal of oncology vol. 5,2 (1994): 169-76. doi: https://doi.org/10.3892/ijo.5.2.169
Rosell R, Li S, Anton A, Moreno I, Martinez E, Vadell C, Mate J, Ariza A, Monzo M, Font A, Molina F, Deanta J, Pifarre A. Prognostic value of k-ras 12 genotypes in patients with advanced nonsmall cell lung-cancer receiving Carboplatin with either intravenous or chronic oral dose Etoposide. Int J Oncol. 1994 Aug;5(2):169-76. doi: 10.3892/ijo.5.2.169. PMID: 21559571.
Copy Download .nbib Format: NLM
Detection of collagen triple helix repeat containing-1 and nuclear factor (erythroid-derived 2)-like 3 in colorectal cancer.

BMC clinical pathology

Palma M, Lopez L, García M, de Roja N, Ruiz T, García J, Rosell E, Vela C, Rueda P, Rodriguez MJ.
PMID: 22321245
BMC Clin Pathol. 2012 Feb 09;12:2. doi: 10.1186/1472-6890-12-2.

BACKGROUND: Collagen Triple Helix Repeat Containing-1 (CTHRC1) and Nuclear factor (erythroid-derived 2)-like 3 (NFE2L3) may be useful biomarker candidates for the diagnosis of colorectal cancer (CRC) since they have shown an increase messenger RNA transcripts (mRNA) expression level in...

Cite
Palma M, Lopez L, García M, et al. Detection of collagen triple helix repeat containing-1 and nuclear factor (erythroid-derived 2)-like 3 in colorectal cancer. BMC Clin Pathol. 2012;12:2doi: 10.1186/1472-6890-12-2.
Palma, M., Lopez, L., García, M., de Roja, N., Ruiz, T., García, J., Rosell, E., Vela, C., Rueda, P., & Rodriguez, M. J. (2012). Detection of collagen triple helix repeat containing-1 and nuclear factor (erythroid-derived 2)-like 3 in colorectal cancer. BMC clinical pathology, 122. https://doi.org/10.1186/1472-6890-12-2
Palma, Marco, et al. "Detection of collagen triple helix repeat containing-1 and nuclear factor (erythroid-derived 2)-like 3 in colorectal cancer." BMC clinical pathology vol. 12 (2012): 2. doi: https://doi.org/10.1186/1472-6890-12-2
Palma M, Lopez L, García M, de Roja N, Ruiz T, García J, Rosell E, Vela C, Rueda P, Rodriguez MJ. Detection of collagen triple helix repeat containing-1 and nuclear factor (erythroid-derived 2)-like 3 in colorectal cancer. BMC Clin Pathol. 2012 Feb 09;12:2. doi: 10.1186/1472-6890-12-2. PMID: 22321245; PMCID: PMC3293008.
Copy Download .nbib Format: NLM
Comparison of three schemes of two-photon laser-induced fluorescence for CO detection in flames.

Applied spectroscopy

Rosell J, Sjöholm J, Richter M, Aldén M.
PMID: 23452496
Appl Spectrosc. 2013 Mar;67(3):314-20. doi: 10.1366/12-06704.

Two-photon excitation laser-induced fluorescence of carbon monoxide suffers from interference from mainly C2 and strong pressure quenching. This paper presents an investigation of three excitation/detection schemes for two-photon excitation laser-induced fluorescence on carbon monoxide. The schemes are evaluated for...

Cite
Rosell J, Sjöholm J, Richter M, et al. Comparison of three schemes of two-photon laser-induced fluorescence for CO detection in flames. Appl Spectrosc. 2013;67(3):314-20doi: 10.1366/12-06704.
Rosell, J., Sjöholm, J., Richter, M., & Aldén, M. (2013). Comparison of three schemes of two-photon laser-induced fluorescence for CO detection in flames. Applied spectroscopy, 67(3), 314-20. https://doi.org/10.1366/12-06704
Rosell, Joakim, et al. "Comparison of three schemes of two-photon laser-induced fluorescence for CO detection in flames." Applied spectroscopy vol. 67,3 (2013): 314-20. doi: https://doi.org/10.1366/12-06704
Rosell J, Sjöholm J, Richter M, Aldén M. Comparison of three schemes of two-photon laser-induced fluorescence for CO detection in flames. Appl Spectrosc. 2013 Mar;67(3):314-20. doi: 10.1366/12-06704. PMID: 23452496.
Copy Download .nbib Format: NLM
Nuclear and mitochondrial genetic structure in the Eurasian beaver (Castor fiber) - implications for future reintroductions.

Evolutionary applications

Senn H, Ogden R, Frosch C, Syrůčková A, Campbell-Palmer R, Munclinger P, Durka W, Kraus RH, Saveljev AP, Nowak C, Stubbe A, Stubbe M, Michaux J, Lavrov V, Samiya R, Ulevicius A, Rosell F.
PMID: 25067948
Evol Appl. 2014 Jun;7(6):645-62. doi: 10.1111/eva.12162. Epub 2014 Jun 17.

Many reintroduction projects for conservation fail, and there are a large number of factors that may contribute to failure. Genetic analysis can be used to help stack the odds of a reintroduction in favour of success, by conducting assessment...

Cite
Senn H, Ogden R, Frosch C, et al. Nuclear and mitochondrial genetic structure in the Eurasian beaver (Castor fiber) - implications for future reintroductions. Evol Appl. 2014;7(6):645-62doi: 10.1111/eva.12162.
Senn, H., Ogden, R., Frosch, C., Syrůčková, A., Campbell-Palmer, R., Munclinger, P., Durka, W., Kraus, R. H., Saveljev, A. P., Nowak, C., Stubbe, A., Stubbe, M., Michaux, J., Lavrov, V., Samiya, R., Ulevicius, A., & Rosell, F. (2014). Nuclear and mitochondrial genetic structure in the Eurasian beaver (Castor fiber) - implications for future reintroductions. Evolutionary applications, 7(6), 645-62. https://doi.org/10.1111/eva.12162
Senn, Helen, et al. "Nuclear and mitochondrial genetic structure in the Eurasian beaver (Castor fiber) - implications for future reintroductions." Evolutionary applications vol. 7,6 (2014): 645-62. doi: https://doi.org/10.1111/eva.12162
Senn H, Ogden R, Frosch C, Syrůčková A, Campbell-Palmer R, Munclinger P, Durka W, Kraus RH, Saveljev AP, Nowak C, Stubbe A, Stubbe M, Michaux J, Lavrov V, Samiya R, Ulevicius A, Rosell F. Nuclear and mitochondrial genetic structure in the Eurasian beaver (Castor fiber) - implications for future reintroductions. Evol Appl. 2014 Jun;7(6):645-62. doi: 10.1111/eva.12162. Epub 2014 Jun 17. PMID: 25067948; PMCID: PMC4105916.
Copy Download .nbib Format: NLM
From the Lab to the Front Line: How Individual Biogerontologists Navigate their Contested Field.

Journal of aging studies

Settersten RA, Flatt MA, Ponsaran RS.
PMID: 19956361
J Aging Stud. 2008 Dec 01;22(4):304-312. doi: 10.1016/j.jaging.2008.05.002.

This paper infuses a new perspective into scholarship on anti-aging science: the experiences of individual scientists as they entered and navigate this controversial field. We draw on in-depth interviews with 43 prominent biogerontologists to accomplish three objectives. First, we...

Cite
Settersten RA, Flatt MA, Ponsaran RS. From the Lab to the Front Line: How Individual Biogerontologists Navigate their Contested Field. J Aging Stud. 2008;22(4):304-312doi: 10.1016/j.jaging.2008.05.002.
Settersten, R. A., Flatt, M. A., & Ponsaran, R. S. (2008). From the Lab to the Front Line: How Individual Biogerontologists Navigate their Contested Field. Journal of aging studies, 22(4), 304-312. https://doi.org/10.1016/j.jaging.2008.05.002
Settersten, Richard A, et al. "From the Lab to the Front Line: How Individual Biogerontologists Navigate their Contested Field." Journal of aging studies vol. 22,4 (2008): 304-312. doi: https://doi.org/10.1016/j.jaging.2008.05.002
Settersten RA, Flatt MA, Ponsaran RS. From the Lab to the Front Line: How Individual Biogerontologists Navigate their Contested Field. J Aging Stud. 2008 Dec 01;22(4):304-312. doi: 10.1016/j.jaging.2008.05.002. PMID: 19956361; PMCID: PMC2669316.
Copy Download .nbib Format: NLM
Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma.

Ecancermedicalscience

De Pas T, Spitaleri G, Vigna PD, Toffalorio F, Curigliano G, Gambino A, Boselli S, Catania C, de Braud F.
PMID: 22275981
Ecancermedicalscience. 2008;2:102. doi: 10.3332/ecancer.2008.102. Epub 2008 Nov 24.

BACKGROUND: despite the fact that the combination of gemcitabine (GCB) and docetaxel shows an increased benefit for disease-free survival and overall survival compared to GCB alone in patients with soft-tissue sarcoma, GCB mono-chemotherapy should be considered as a preferable...

Cite
De Pas T, Spitaleri G, Vigna PD, et al. Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma. Ecancermedicalscience. 2008;2:102doi: 10.3332/ecancer.2008.102.
De Pas, T., Spitaleri, G., Vigna, P. D., Toffalorio, F., Curigliano, G., Gambino, A., Boselli, S., Catania, C., & de Braud, F. (2008). Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma. Ecancermedicalscience, 2102. https://doi.org/10.3332/ecancer.2008.102
De Pas, T, et al. "Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma." Ecancermedicalscience vol. 2 (2008): 102. doi: https://doi.org/10.3332/ecancer.2008.102
De Pas T, Spitaleri G, Vigna PD, Toffalorio F, Curigliano G, Gambino A, Boselli S, Catania C, de Braud F. Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma. Ecancermedicalscience. 2008;2:102. doi: 10.3332/ecancer.2008.102. Epub 2008 Nov 24. PMID: 22275981; PMCID: PMC3234072.
Copy Download .nbib Format: NLM
A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis.

Journal of clinical and experimental hepatology

Mehta G, Rousell S, Burgess G, Morris M, Wright G, McPherson S, Frenette C, Cave M, Hagerty DT, Spada A, Jalan R.
PMID: 30302038
J Clin Exp Hepatol. 2018 Sep;8(3):224-234. doi: 10.1016/j.jceh.2017.11.006. Epub 2017 Nov 22.

BACKGROUND: Cirrhosis and acute-on-chronic liver failure (ACLF) are associated with systemic inflammation, and caspase-mediated hepatocyte cell death. Emricasan is a novel, pan-caspase inhibitor. Aims of this study were to assess the pharmacokinetics, pharmacodynamics, safety and clinical outcomes of emricasan...

Cite
Mehta G, Rousell S, Burgess G, et al. A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis. J Clin Exp Hepatol. 2017;8(3):224-234doi: 10.1016/j.jceh.2017.11.006.
Mehta, G., Rousell, S., Burgess, G., Morris, M., Wright, G., McPherson, S., Frenette, C., Cave, M., Hagerty, D. T., Spada, A., & Jalan, R. (2018). A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis. Journal of clinical and experimental hepatology, 8(3), 224-234. https://doi.org/10.1016/j.jceh.2017.11.006
Mehta, Gautam, et al. "A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis." Journal of clinical and experimental hepatology vol. 8,3 (2018): 224-234. doi: https://doi.org/10.1016/j.jceh.2017.11.006
Mehta G, Rousell S, Burgess G, Morris M, Wright G, McPherson S, Frenette C, Cave M, Hagerty DT, Spada A, Jalan R. A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis. J Clin Exp Hepatol. 2018 Sep;8(3):224-234. doi: 10.1016/j.jceh.2017.11.006. Epub 2017 Nov 22. PMID: 30302038; PMCID: PMC6175779.
Copy Download .nbib Format: NLM
Increasing the discrimination power of rapid evaporative ionisation mass spectrometry (REIMS) in analytical control tissue quality screening and cell line sample identification.

Rapid communications in mass spectrometry : RCM

Abu-Rabie P, Sheelan D, Laures A, Spaull J, Dowell S.
PMID: 31295371
Rapid Commun Mass Spectrom. 2019 Jul 11; doi: 10.1002/rcm.8525. Epub 2019 Jul 11.

RATIONALE: Rapid Evaporative Ionisation Mass Spectrometry (REIMS) has been evaluated as a tool to improve analytical efficiency and add capability in areas within Pharmaceutical Research and Development (Pharma R&D). This article reports the comparison of single MS, and tandem...

Cite
Abu-Rabie P, Sheelan D, Laures A, et al. Increasing the discrimination power of rapid evaporative ionisation mass spectrometry (REIMS) in analytical control tissue quality screening and cell line sample identification. Rapid Commun Mass Spectrom. 2019;doi: 10.1002/rcm.8525.
Abu-Rabie, P., Sheelan, D., Laures, A., Spaull, J., & Dowell, S. (2019). Increasing the discrimination power of rapid evaporative ionisation mass spectrometry (REIMS) in analytical control tissue quality screening and cell line sample identification. Rapid communications in mass spectrometry : RCM, . https://doi.org/10.1002/rcm.8525
Abu-Rabie, Paul, et al. "Increasing the discrimination power of rapid evaporative ionisation mass spectrometry (REIMS) in analytical control tissue quality screening and cell line sample identification." Rapid communications in mass spectrometry : RCM vol. (2019). doi: https://doi.org/10.1002/rcm.8525
Abu-Rabie P, Sheelan D, Laures A, Spaull J, Dowell S. Increasing the discrimination power of rapid evaporative ionisation mass spectrometry (REIMS) in analytical control tissue quality screening and cell line sample identification. Rapid Commun Mass Spectrom. 2019 Jul 11; doi: 10.1002/rcm.8525. Epub 2019 Jul 11. PMID: 31295371.
Copy Download .nbib Format: NLM
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.

Therapeutic advances in medical oncology

Karachaliou N, Gonzalez-Cao M, Crespo G, Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, Teixido C, Molina-Vila MA, Viteri S, De Los Llanos Gil M, Algarra SM, Perez-Ruiz E, Marquez-Rodas I, Rodriguez-Abreu D, Blanco R, Puertolas T, Royo MA, Rosell R.
PMID: 29383037
Ther Adv Med Oncol. 2018 Jan 18;10:1758834017749748. doi: 10.1177/1758834017749748. eCollection 2018.

BACKGROUND: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated METHODS: Total RNA from 17 NSCLC and 21 melanoma patients was analyzed by quantitative reverse transcription PCR. STAT3 and Rantes, YAP1 and CXCL5, DNMT1,...

Cite
Karachaliou N, Gonzalez-Cao M, Crespo G, et al. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther Adv Med Oncol. 2018;10:1758834017749748doi: 10.1177/1758834017749748.
Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., Algarra, S. M., Perez-Ruiz, E., Marquez-Rodas, I., Rodriguez-Abreu, D., Blanco, R., Puertolas, T., Royo, M. A., & Rosell, R. (2018). Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Therapeutic advances in medical oncology, 101758834017749748. https://doi.org/10.1177/1758834017749748
Karachaliou, Niki, et al. "Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients." Therapeutic advances in medical oncology vol. 10 (2018): 1758834017749748. doi: https://doi.org/10.1177/1758834017749748
Karachaliou N, Gonzalez-Cao M, Crespo G, Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, Teixido C, Molina-Vila MA, Viteri S, De Los Llanos Gil M, Algarra SM, Perez-Ruiz E, Marquez-Rodas I, Rodriguez-Abreu D, Blanco R, Puertolas T, Royo MA, Rosell R. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther Adv Med Oncol. 2018 Jan 18;10:1758834017749748. doi: 10.1177/1758834017749748. eCollection 2018. PMID: 29383037; PMCID: PMC5784541.
Copy Download .nbib Format: NLM
Compound-Specific Chlorine Isotope Analysis of Tetrachloromethane and Trichloromethane by Gas Chromatography-Isotope Ratio Mass Spectrometry vs Gas Chromatography-Quadrupole Mass Spectrometry: Method Development and Evaluation of Precision and Trueness.

Analytical chemistry

Heckel B, Rodríguez-Fernández D, Torrentó C, Meyer A, Palau J, Domènech C, Rosell M, Soler A, Hunkeler D, Elsner M.
PMID: 28193000
Anal Chem. 2017 Mar 21;89(6):3411-3420. doi: 10.1021/acs.analchem.6b04129. Epub 2017 Mar 02.

Compound-specific chlorine isotope analysis of tetrachloromethane (CCl

Cite
Heckel B, Rodríguez-Fernández D, Torrentó C, et al. Compound-Specific Chlorine Isotope Analysis of Tetrachloromethane and Trichloromethane by Gas Chromatography-Isotope Ratio Mass Spectrometry vs Gas Chromatography-Quadrupole Mass Spectrometry: Method Development and Evaluation of Precision and Trueness. Anal Chem. 2017;89(6):3411-3420doi: 10.1021/acs.analchem.6b04129.
Heckel, B., Rodríguez-Fernández, D., Torrentó, C., Meyer, A., Palau, J., Domènech, C., Rosell, M., Soler, A., Hunkeler, D., & Elsner, M. (2017). Compound-Specific Chlorine Isotope Analysis of Tetrachloromethane and Trichloromethane by Gas Chromatography-Isotope Ratio Mass Spectrometry vs Gas Chromatography-Quadrupole Mass Spectrometry: Method Development and Evaluation of Precision and Trueness. Analytical chemistry, 89(6), 3411-3420. https://doi.org/10.1021/acs.analchem.6b04129
Heckel, Benjamin, et al. "Compound-Specific Chlorine Isotope Analysis of Tetrachloromethane and Trichloromethane by Gas Chromatography-Isotope Ratio Mass Spectrometry vs Gas Chromatography-Quadrupole Mass Spectrometry: Method Development and Evaluation of Precision and Trueness." Analytical chemistry vol. 89,6 (2017): 3411-3420. doi: https://doi.org/10.1021/acs.analchem.6b04129
Heckel B, Rodríguez-Fernández D, Torrentó C, Meyer A, Palau J, Domènech C, Rosell M, Soler A, Hunkeler D, Elsner M. Compound-Specific Chlorine Isotope Analysis of Tetrachloromethane and Trichloromethane by Gas Chromatography-Isotope Ratio Mass Spectrometry vs Gas Chromatography-Quadrupole Mass Spectrometry: Method Development and Evaluation of Precision and Trueness. Anal Chem. 2017 Mar 21;89(6):3411-3420. doi: 10.1021/acs.analchem.6b04129. Epub 2017 Mar 02. PMID: 28193000.
Copy Download .nbib Format: NLM
Neutrophils dominate the immune landscape of non-small cell lung cancer.

Journal of thoracic disease

Teixidó C, Rosell R.
PMID: 28616311
J Thorac Dis. 2017 May;9(5):E468-E469. doi: 10.21037/jtd.2017.04.55.

No abstract available.

Cite
Teixidó C, Rosell R. Neutrophils dominate the immune landscape of non-small cell lung cancer. J Thorac Dis. 2017;9(5):E468-E469doi: 10.21037/jtd.2017.04.55.
Teixidó, C., & Rosell, R. (2017). Neutrophils dominate the immune landscape of non-small cell lung cancer. Journal of thoracic disease, 9(5), E468-E469. https://doi.org/10.21037/jtd.2017.04.55
Teixidó, Cristina, and Rosell, Rafael. "Neutrophils dominate the immune landscape of non-small cell lung cancer." Journal of thoracic disease vol. 9,5 (2017): E468-E469. doi: https://doi.org/10.21037/jtd.2017.04.55
Teixidó C, Rosell R. Neutrophils dominate the immune landscape of non-small cell lung cancer. J Thorac Dis. 2017 May;9(5):E468-E469. doi: 10.21037/jtd.2017.04.55. PMID: 28616311; PMCID: PMC5465158.
Copy Download .nbib Format: NLM
Targeting PD-1/PD-L1 in lung cancer: current perspectives.

Lung Cancer (Auckland, N.Z.)

González-Cao M, Karachaliou N, Viteri S, Morales-Espinosa D, Teixidó C, Sánchez Ruiz J, Molina-Vila MÁ, Santarpia M, Rosell R.
PMID: 28210151
Lung Cancer (Auckl). 2015 Jul 31;6:55-70. doi: 10.2147/LCTT.S55176. eCollection 2015.

Increased understanding of tumor immunology has led to the development of effective immunotherapy treatments. One of the most important advances in this field has been due to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/PD-L1 antibodies are currently...

Cite
González-Cao M, Karachaliou N, Viteri S, et al. Targeting PD-1/PD-L1 in lung cancer: current perspectives. Lung Cancer (Auckl). 2015;6:55-70doi: 10.2147/LCTT.S55176.
González-Cao, M., Karachaliou, N., Viteri, S., Morales-Espinosa, D., Teixidó, C., Sánchez Ruiz, J., Molina-Vila, M. �. �., Santarpia, M., & Rosell, R. (2015). Targeting PD-1/PD-L1 in lung cancer: current perspectives. Lung Cancer (Auckland, N.Z.), 655-70. https://doi.org/10.2147/LCTT.S55176
González-Cao, María, et al. "Targeting PD-1/PD-L1 in lung cancer: current perspectives." Lung Cancer (Auckland, N.Z.) vol. 6 (2015): 55-70. doi: https://doi.org/10.2147/LCTT.S55176
González-Cao M, Karachaliou N, Viteri S, Morales-Espinosa D, Teixidó C, Sánchez Ruiz J, Molina-Vila MÁ, Santarpia M, Rosell R. Targeting PD-1/PD-L1 in lung cancer: current perspectives. Lung Cancer (Auckl). 2015 Jul 31;6:55-70. doi: 10.2147/LCTT.S55176. eCollection 2015. PMID: 28210151; PMCID: PMC5217517.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 397 entries